RecruitingNot ApplicableNCT05833386

Effect of Preoperative Silodosin on Feasibility of Ureteral Access Sheath Insertion

Effect of Preoperative Silodosin on Feasibility of Ureteral Access Sheath Insertion for Flexible Ureteroscope in Treating Renal Stones; A Prospective, Multicentre, Randomized Trial


Sponsor

Al-Azhar University

Enrollment

2,000 participants

Start Date

Oct 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The ureteral access sheath (UAS) is an ancillary device widely used by urologists to facilitate fast, repeatable, and safe access to ureters and collecting systems; improve visibility; reduce the risk of infection by reducing intrarenal pressure; and protect ureters and scopes when extracting multiple stones during surgery. Insertion of ureteric access sheath may be difficult due to tight ureter, so sometimes preoperative stenting might be needed. Silodosin is an α1A adrenoceptor with high affinity and selectivity for the ureteric muscle, which may reduce ureteral spasm. Oral a1-blockers can reduce intraureteral pressure, and may reduce maximal ureteral access sheath insertion force.¹ Preoperative silodosin protects against significant ureteral injury related to UAS insertion during fURS and decreases postoperative pain level. Silodosin premedication might be an effective and safe technique to replace prestenting.²


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • All patients with renal stones who will undergo flexible ureteroscopy and planned for using ureteral access sheath

Exclusion Criteria1

  • Paediatric age group (less than 18 year)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREUreteral access sheath placement during flexible ureteroscope for renal stones

Ureteral access sheath placement during flexible ureteroscope


Locations(1)

Urology department - AlAzhar university

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05833386


Related Trials